Literature DB >> 35585121

Role of neoadjuvant chemoimmunotherapy for resectable NSCLC.

Boris Sepesi1, Stephen G Swisher2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35585121     DOI: 10.1038/s41571-022-00647-9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   65.011


× No keyword cloud information.
  1 in total

1.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jonathan Spicer; Shun Lu; Mariano Provencio; Tetsuya Mitsudomi; Mark M Awad; Enriqueta Felip; Stephen R Broderick; Julie R Brahmer; Scott J Swanson; Keith Kerr; Changli Wang; Tudor-Eliade Ciuleanu; Gene B Saylors; Fumihiro Tanaka; Hiroyuki Ito; Ke-Neng Chen; Moishe Liberman; Everett E Vokes; Janis M Taube; Cecile Dorange; Junliang Cai; Joseph Fiore; Anthony Jarkowski; David Balli; Mark Sausen; Dimple Pandya; Christophe Y Calvet; Nicolas Girard
Journal:  N Engl J Med       Date:  2022-04-11       Impact factor: 176.079

  1 in total
  1 in total

1.  Smoke-induced SAV1 Gene Promoter Hypermethylation Disrupts YAP Negative Feedback and Promotes Malignant Progression of Non-small Cell Lung Cancer.

Authors:  Ting Liu; Wei Guo; Kai Luo; Lei Li; Jing Dong; Meijun Liu; Xingyuan Shi; Zhiyuan Wang; Jianlei Zhang; Jiang Yin; Ni Qiu; Minying Lu; Danyang Chen; Xiaoting Jia; Hao Liu; Yixue Gu; Yan Xiong; Guopei Zheng; Gang Xu; Zhimin He; Zhijie Zhang
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.